BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/18/2020 12:27:09 PM | Browse: 626 | Download: 1322
 |
Received |
|
2020-03-21 19:33 |
|
Peer-Review Started |
|
2020-03-21 19:34 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-09-24 20:08 |
|
Revised |
|
2020-09-28 12:53 |
|
Second Decision |
|
2020-10-21 12:44 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2020-10-21 16:50 |
|
Articles in Press |
|
2020-10-21 16:50 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2020-10-27 01:42 |
|
Typeset the Manuscript |
|
2020-12-16 06:55 |
|
Publish the Manuscript Online |
|
2020-12-18 12:27 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Hematology |
| Manuscript Type |
Minireviews |
| Article Title |
Predictive indicators of successful tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Ruth Stuckey, Juan Francisco López-Rodríguez, Santiago Sánchez-Sosa, Adrián Segura-Díaz, Nuria Sanchéz-Farías, Cristina Bilbao-Sieyro and María Teresa Gómez-Casares |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
María Teresa Gómez-Casares, MD, PhD, Chief Doctor, Department of Hematology, Hospital Universitario de Gran Canaria Dr. Negrín, Barranco de la Ballena s/n, Las Palmas de Gran Canaria 35019, Las Palmas de Gran Canaria, Spain. mgomcasf@gobiernodecanarias.org |
| Key Words |
Biomarkers; Tyrosine kinase inhibitors; Treatment discontinuation; Molecular monitoring; Duration of therapy; Leukemia; Myelogenous; Chronic; BCR-ABL positive |
| Core Tip |
Clinical trials have shown that approximately 50% of patients with chronic myeloid leukemia who reach a deep molecular response (MR) following treatment for several years with tyrosine kinase inhibitors (TKI) can discontinue and remain in treatment-free remission (TFR). Factors such as the duration of TKI treatment and duration and depth of the patient’s MR prior to discontinuation appear to be important in determining whether TFR is achieved. However, it is clear that other biological factors must determine whether an individual will remain in TFR after discontinuation. Future studies should aim to elucidate biomarkers predictive of TFR. |
| Publish Date |
2020-12-18 12:27 |
| Citation |
Stuckey R, López-Rodríguez JF, Sánchez-Sosa S, Segura-Díaz A, Sánchez-Farías N, Bilbao-Sieyro C, Gomez-Casares MT. Predictive indicators of successful tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia. World J Clin Oncol 2020; 11(12): 996-1007 |
| URL |
https://www.wjgnet.com/2218-4333/full/v11/i12/996.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v11.i12.996 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
